BG-4, a novel bioactive peptide from momordica charantia, inhibits lipopolysaccharide-induced inflammation in THP-1 human macrophages
BG-4, a novel bioactive peptide from momordica charantia, inhibits lipopolysaccharide-induced inflammation in THP-1 human macrophages
LD Jones, P Pangloli, HB Krishnan, VP Dia - Phytomedicine, 2018 - Elsevier
Abstract Background Bitter melon (Momordica charantia) is a commonly used food crop for
management of a variety of diseases most notably for control of diabetes, a disease
associated with aberrant inflammation. Purpose To evaluate the anti-inflammatory property …
management of a variety of diseases most notably for control of diabetes, a disease
associated with aberrant inflammation. Purpose To evaluate the anti-inflammatory property …
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Ronnie Ji
ronnie@pepmic.com
Pepmic Co., Ltdronnie@pepmic.com
www.pepmic.com
评论
发表评论